| SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展 |
| 投稿时间：2020-06-16 修订日期：2020-09-07 点此下载全文 |
| 引用本文：赖彦岚,黄爱文,张丽丽,廖小兰,赵丽君,宋洪涛.SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展[J].药学实践杂志,2020,38(6):496~500,567 |
| 摘要点击次数: 1057 |
| 全文下载次数: 1089 |
|
|
| 中文摘要:2型糖尿病是动脉粥样硬化性心血管疾病发病的高危因素。研究发现，钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂、胰高血糖素样多肽-1(GLP-1)受体激动剂对2型糖尿病合并心血管疾病的患者具有心血管保护作用。故从心血管安全性试验及其Meta分析、网状Meta分析方面，对SGLT-2抑制剂、GLP-1受体激动剂的心血管安全性研究进展进行归纳和总结。 |
| 中文关键词:SGLT-2抑制剂 GLP-1受体激动剂 2型糖尿病 心血管安全性 |
| |
| Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists |
|
|
| Abstract:Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized. |
| keywords:SGLT-2 inhibitors GLP-1 receptor agonists type 2 diabetes cardiovascular safety |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
